|
Oncology Here & NOWThe top topics in oncology, delivered every 10 days by a diverse and highly specialized team of oncologists and urologists from around the world.
The Oncoalert Team brings you relevant and concise 10-minute episodes, three times a month, every month. Hosts:
|
Season 2 (Sept 2025-Current)
|
Cancer Statistics 2025 out on CA by the American Cancer Society with Dr. Morgan and lead author Mr. Kratzer (Sept 25, 2025)
Join Dr. Gil Morgan in conversation with Mr. Tyler Kratzer of the American Cancer Society, lead author of Prostate Cancer Statistics 2025 (published in CA: A Cancer Journal for Clinicians). 📖 Read the paper here: https://acsjournals.onlinelibrary.wil... Key Insights: ⚠️ Racial disparities persist: Black men: 2× higher mortality & 67% higher incidence American Indian/Alaska Native men: 12% higher mortality despite lower incidence Asian American/Pacific Islander & Hispanic men: less often diagnosed with localized disease 👉 Take-home message: Rising rates of advanced prostate cancer and persistent disparities underscore the urgent need to improve early detection strategies, avoid overdiagnosis, and address inequities in outcomes. |
Oncology Here & Now with Dr. Danny Mena, Hosted by Dr. Barbara Melão (Sept 7, 2025)
Join Dr. Barbara Melão (Brazil) and Dr. Danny Mena (Mexico) as they kick off Season 2 with a deep dive into GU Oncology and the latest advances in Prostate Cancer care. In this episode, they explore: Key Insights: ✅ The rationale behind the BULLSEYE 🎯 Trial ✅ Key differences between Lutetium & Terbium ✅ Understanding Affinity 🆚 Toxicity ✅ Follow-up strategies for patients with PSMA PET …and much more cutting-edge insights! |
Season 1 (March to June 2025)
|
|
|
|
Treatment of Upper Tract Urothelial Carcinoma with Dr. Melão and Dr. Spiess
(May 20, 2025) Join our Urology colleagues, Dr. Melao and Dr. Spiess, as they discuss upper tract urothelial carcinoma—from risk stratification to management strategies in both low-risk and high-risk, high-grade settings. They’ll also explore long-term renal function outcomes, a topic on which Dr. Spiess has recently published. |
Annual Report to the Nation on the Status of Cancer with Dr. Jemal and Dr. Morgan
(April 28, 2025) Join Dr. Jemal & Dr Morgan as they discuss this report, a collaboration among major U.S. cancer surveillance organizations, presents the latest national data on cancer incidence and mortality. Using data from cancer registries and national vital statistics, the analysis shows that while overall cancer death rates have steadily declined over the past 20 years — including during the COVID-19 pandemic — the annual rate of decline has recently slowed. Cancer incidence rates remained stable among males and rose slightly among females over time, with a temporary dip across all groups in 2020 likely due to pandemic-related disruptions in healthcare access. However, incidence rates rebounded to prepandemic levels by 2021, suggesting a limited long-term impact of COVID-19 on cancer detection trends. |
|
|
|
|
First Line Therapy in EGFR mutant NSCLC with Dr. Marcelo Corassa & Dr. Biagio Ricciuti (April 14, 2025)
In this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lung Cancer. The discussion centers around the results of FLAURA, MARIPOSA and FLAURA2, future directions and much more. Join Us |
Supportive Care & Telemedicine with Dr. Joseph McCollom & Dr. Cristiane Bergerot (March 26, 2025)
In this Interview Dr. McCollom & Dr. Bergerot discuss Telehealth. Dr. Bergerot, a psychologist and head of Supportive Care at Groupo Clinicas in Brazil dives into the critical role of TeleHealth in oncology and palliative care, focusing on how the COVID-19 pandemic accelerated the adoption of TeleHealth globally and its continued integration into healthcare systems, particularly for improving access to care in remote and underserved areas. |
|
|
|
|
Breast Cancer with Dr. Agostinetto & Dr. Lustberg Discussing Adj CDK4/6 inhibitors (March 14, 2025)
In this interview, Dr. Elisa Agostinetto from the Jules Bordet Institute in Belgium speaks with Dr. Maryam Lustberg from Yale Cancer Center. Together, they dive deep into the use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer. Their discussion covers the use of Abemaciclib and Ribociclib following the monarchE and NATALEE trials, applications in the treatment of male breast cancer, and much more. |
Prostate Cancer with Dr. Silke Gillessen & Dr.Aurelius Omlin of APCCC
(March 5, 2025) this interview with Dr. Silke Gillessen and Dr. Aurelius Omlin, we explore the origins and evolution of the Advanced Prostate Cancer Consensus Conference (APCCC), launched in 2015 to address areas of uncertainty in prostate cancer management. Topics over the years have included oligometastatic disease, treatment sequencing, and new imaging. The 2024 APCCC emphasized next-generation imaging, genomic biomarkers, and the balance between innovation and practicality. Looking to 2026, discussions will focus on overtreatment risks, global disparities in imaging access, and incorporating comorbidities into treatment decisions, while continuing to welcome international participation. |